BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 22492777)

  • 21. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
    Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
    BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
    Benn DE; Croxson MS; Tucker K; Bambach CP; Richardson AL; Delbridge L; Pullan PT; Hammond J; Marsh DJ; Robinson BG
    Oncogene; 2003 Mar; 22(9):1358-64. PubMed ID: 12618761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
    Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
    Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.
    Bayley JP; van Minderhout I; Weiss MM; Jansen JC; Oomen PH; Menko FH; Pasini B; Ferrando B; Wong N; Alpert LC; Williams R; Blair E; Devilee P; Taschner PE
    BMC Med Genet; 2006 Jan; 7():1. PubMed ID: 16405730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
    Baysal BE; Maher ER
    Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
    Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
    Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
    Korpershoek E; Petri BJ; van Nederveen FH; Dinjens WN; Verhofstad AA; de Herder WW; Schmid S; Perren A; Komminoth P; de Krijger RR
    Endocr Relat Cancer; 2007 Jun; 14(2):453-62. PubMed ID: 17639058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.
    Ricketts CJ; Forman JR; Rattenberry E; Bradshaw N; Lalloo F; Izatt L; Cole TR; Armstrong R; Kumar VK; Morrison PJ; Atkinson AB; Douglas F; Ball SG; Cook J; Srirangalingam U; Killick P; Kirby G; Aylwin S; Woodward ER; Evans DG; Hodgson SV; Murday V; Chew SL; Connell JM; Blundell TL; Macdonald F; Maher ER
    Hum Mutat; 2010 Jan; 31(1):41-51. PubMed ID: 19802898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas.
    Dahia PL;
    Ann N Y Acad Sci; 2006 Aug; 1073():208-20. PubMed ID: 17102089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic pheochromocytoma and paraganglioma.
    Angelousi A; Kassi E; Zografos G; Kaltsas G
    Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of the transcription factor snail and its target gene twist are associated with malignancy in pheochromocytomas.
    Waldmann J; Slater EP; Langer P; Buchholz M; Ramaswamy A; Walz MK; Schmid KW; Feldmann G; Bartsch DK; Fendrich V
    Ann Surg Oncol; 2009 Jul; 16(7):1997-2005. PubMed ID: 19412634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Guide to Pheochromocytomas and Paragangliomas.
    Guilmette J; Sadow PM
    Surg Pathol Clin; 2019 Dec; 12(4):951-965. PubMed ID: 31672301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
    Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
    BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening of mutations in genes that predispose to hereditary paragangliomas and pheochromocytomas.
    Lefebvre S; Borson-Chazot F; Boutry-Kryza N; Wion N; Schillo F; Peix JL; Brunaud L; Finat A; Calender A; Giraud S
    Horm Metab Res; 2012 May; 44(5):334-8. PubMed ID: 22517554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
    Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
    Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
    Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EMT-associated factors promote invasive properties of uveal melanoma cells.
    Asnaghi L; Gezgin G; Tripathy A; Handa JT; Merbs SL; van der Velden PA; Jager MJ; Harbour JW; Eberhart CG
    Mol Vis; 2015; 21():919-29. PubMed ID: 26321866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases.
    Toll A; Masferrer E; Hernández-Ruiz ME; Ferrandiz-Pulido C; Yébenes M; Jaka A; Tuneu A; Jucglà A; Gimeno J; Baró T; Casado B; Gandarillas A; Costa I; Mojal S; Peña R; de Herreros AG; García-Patos V; Pujol RM; Hernández-Muñoz I
    J Dermatol Sci; 2013 Nov; 72(2):93-102. PubMed ID: 23928229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis.
    Su T; Yang Y; Jiang L; Xie J; Zhong X; Wu L; Jiang Y; Zhang C; Zhou W; Ye L; Ning G; Wang W
    Front Endocrinol (Lausanne); 2023; 14():1121397. PubMed ID: 37008946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.